Bristol Myers Squibb confirms 5-year benefits of mavacamten

Bristol Myers Squibb (BMS) has presented long-term results from the Explorer-Lte cohort of the Mava-Lte study at the European Society of Cardiology Congress in Munich. The data confirms that the benefits of mavacamten, a cardiac myosin inhibitor, are maintained for up to five years in patients treated with continuous therapy.

The study focused on patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as NYHA class II-III. The Explorer-Lte study serves as a single-arm, open-label extension of the phase 3 Explorer-Hcm blinded study, evaluating the long-term safety and efficacy of the drug.

Anjali T. Owens of the Perelman School of Medicine at the University of Pennsylvania noted that for chronic and progressive diseases, long-term data is essential for helping physicians understand how therapies provide benefits to patients over time.